Physical Therapy in Women With Interstitial Cystitis (IC03)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00733603|
Recruitment Status : Unknown
Verified January 2010 by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
Recruitment status was: Active, not recruiting
First Posted : August 13, 2008
Last Update Posted : January 14, 2010
There are many different treatments that doctors recommend for patients with IC/PBS. Only a few research studies have been done to evaluate treatments given to patients. Treatment choices can be of two types: drug therapy and non-drug therapy. The two treatments used in this study will be of the non-drug therapy type. One of the treatments being used in this study is called Myofascial Tissue Manipulation. This is a kind of physical therapy that is designed to work on specific muscles and tissue layers in a particular part of the body. In this study, this treatment will focus on the areas around the pelvis and the pelvic floor. The treatment will involve the physical therapist's use of hands and fingers to target specific muscles and tissues located within your pelvis, rectum, and/or vagina (the pelvic floor) as well as muscles and layers of tissue in your abdomen and legs. The other treatment being used in this study is Global Therapeutic Massage. This treatment involves the physical therapist's use of classic Western body massage techniques on the muscles of your arms, legs, hands, neck, shoulders, back, stomach, buttocks, and feet to create an overall feeling of well being.
The purpose of this research study is to find out if Pelvic Physical Therapy is safe and effective on treating symptoms in women with interstitial cystitis as compared to a full body therapeutic massage. This study will also measure the lasting effects of the treatment up to 3 months after your last study treatment.
|Condition or disease||Intervention/treatment|
|Interstitial Cystitis Painful Bladder Syndrome||Other: Global Therapeutic Massages (GTM) Other: Myofascial Tissue Manipulation (MTM)|
Hide Detailed Description
The Urologic Pelvic Pain Syndromes (UPPS) are characterized by pelvic pain with concurrent urinary symptoms. Broadly, the UPPS comprise Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS) in men and women, and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) in men, although the focus of this protocol is exclusively women with IC/PBS.
Interstitial Cystitis (IC) is a debilitating bladder disorder characterized by urinary urgency, frequency, and pain. The presentation of symptoms can be quite variable among patients, suggesting that IC is a multi-factorial syndrome with several proposed etiologies, some of which may be interrelated.1 Painful Bladder Syndrome (PBS), as defined by the International Continence Society, is "the complaint of suprapubic pain related to bladder filling, accompanied by other symptoms, such as increased daytime and night-time frequency, in the absence of proven urinary infection or other obvious pathology. 2" PBS is a clinical description of disease based on the patient's symptoms and does not depend on urodynamic or cystoscopic findings. These symptoms may be related to interstitial cystitis, although diagnostic criteria are still lacking for this entity, and the relationship between PBS and interstitial cystitis is not clear. For clarity and compliance with current nomenclature, this protocol will use the term IC/PBS.
As with many chronic pain disorders, IC/PBS is poorly understood, poorly characterized, and treatment is mostly empirical and unsatisfactory. Several proposed etiologic theories include (1) increased bladder epithelial permeability, (2) activation of bladder mast cells, (3) allergic or autoimmune processes, (4) toxic substance(s) in the urine, (5) occult infection, (6) neuropathic changes, and (7) neurogenic inflammation. However, none of these mechanisms have been conclusively shown to be responsible for IC/PBS. Estimates of prevalence of the syndromes vary widely. In 1990 interstitial cystitis (IC) was thought to affect as many as 500,000 U.S. citizens, with 25% of patients under age 25.3 More recently however, using expanded definitions of PBS now exceed 10 million.4 Quality of life with IC/PBS can be worse than end stage renal disease.5 The recent pilot study of manual physical therapies for Urologic Pelvic Pain demonstrated feasibility of recruitment, and promising benefit of myofascial tissue manipulation (MTM) (ref manuscript#1). In that pilot study, 47 participants were recruited to six centers with prior expertise in MTM. Of the 47 participants, 24 were females with IC/PBS, and 23 were males -- 2 with IC/PBS and 21 with CP/CPPS. Motivated by the promising findings in that pilot study, this protocol aims to investigate whether those initial results are generalizable in an expanded phase 3 clinical trial, in which we include other therapists from other centers. However, due to the gender-specific findings of the pilot study, and the limited resources available, this protocol is focused on replicating the initial pilot study exclusively in women with IC/PBS.
Although the pain of IC/PBS is poorly understood, almost all clinicians agree that there is almost always some chronic tension and tenderness of the pelvic floor musculature present in UPPS patients,8-10 and it is possible that these myofascial abnormalities contribute significantly to the pain of IC/PBS. For example, Hetrick et al11 compared the surface EMG signals from men with CPPS to those from men without chronic pain, and found that there was greater EMG instability in men with CPPS, along with increased baseline tonicity, and instability with lowered voluntary endurance contraction amplitude.
Whether these musculoskeletal abnormalities of the abdominal wall and pelvic floor musculature found in IC/PBS sufferers represent primary or secondary phenomena remains unknown. It is possible that pelvic visceral pain leads to chronic contraction of regional skeletal musculature, leading to overuse injury and pain. It is also possible that primary pelvic myofascial problems lead to painful and weakened pelvic floor musculature, which also functions poorly to inhibit the urgency associated with bladder filling.
Our prior study of manual physical therapy suggested benefit of MTM over GTM. Translation of those office practices into the research setting was apparently successful in centers that participated in the first trial. We propose to expand the number of treating therapists to include 11 study centers, in order to determine whether the results of the first trial can be generalized, at least in the research setting. However, due to the gender-specific findings, this expanded replication study will focus exclusively on women with IC/PBS.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||88 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Single-Blinded Randomized Multi-Center Trial to Evaluate the Efficacy and Durability of Myofascial Tissue Manipulation in Women With Interstitial Cystitis/Painful Bladder Syndrome|
|Study Start Date :||June 2008|
|Estimated Primary Completion Date :||February 2009|
|Estimated Study Completion Date :||May 2009|
Sham Comparator: 1
Global Therapeutic Massage (GTM)
Other: Global Therapeutic Massages (GTM)
Non-specific somatic treatment with full-body Western massage.
Active Comparator: 2
Myofascial Tissue Manipulation (MTM)
Other: Myofascial Tissue Manipulation (MTM)
Targeted internal and external Connective Tissue Manipulation focusing on the muscles and connective tissues of the pelvic floor, hip girdle, and abdomen.
- To determine the efficacy, safety and tolerability of Myofascial Tissue Manipulation (MTM) in women with IC/PBS, as compared to Global Therapeutic Massage (GTM). [ Time Frame: 12 Weeks ]
- To determine the durability of Myofascial Tissue Manipulation (MTM) in women with IC/PBS, as compared to Global Therapeutic Massage (GTM). [ Time Frame: 12 Weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00733603
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00733603
|United States, California|
|Univeristy of California San Diego|
|San Diego, California, United States, 92093|
|Stanford University Medical center|
|Stanford, California, United States, 94305|
|United States, Illinois|
|Loyola University Medical Center|
|Maywood, Illinois, United States, 60153|
|United States, Iowa|
|University of Iowa Hospitals and Clinic|
|Iowa City, Iowa, United States, 52242|
|United States, Maryland|
|University of Maryland|
|Baltimore, Maryland, United States, 21201|
|United States, Michigan|
|Henry Ford Hospital|
|Detroit, Michigan, United States, 48202|
|William Beaumont Hospital|
|Royal Oak, Michigan, United States, 48073|
|United States, New York|
|University of Rochester Medical Center|
|Rochester, New York, United States, 14642|
|United States, Pennsylvania|
|University of Pennsylvania Health System|
|Philadelphia, Pennsylvania, United States, 19104|
|United States, Washington|
|University of Washington|
|Seattle, Washington, United States, 98195|
|Kingston, Ontario, Canada, K7L2V7|
|Study Director:||LeRoy M Nyberg, MD, PhD||NIDDK/NIH|
|Study Chair:||Mary P Fitzgerald, MD||Loyola University|
|Principal Investigator:||Richard Landis, PhD||University of Pennsylvania|
|Principal Investigator:||Robert Mayer, MD||University of Rochester|
|Principal Investigator:||Emily Lukacz, MD||University of California, San Diego|
|Principal Investigator:||Kenneth Peters, MD||William Beaumont Hospital, Royal Oak, MI|
|Principal Investigator:||Toby Chai, MD||University of Maryland|
|Principal Investigator:||Christopher Payne, MD||Stanford University|
|Principal Investigator:||Claire Yang, MD||University of Washington|
|Principal Investigator:||Phillip Hanno, MD||University of Pennsylvania|
|Principal Investigator:||Karl Kreder, MD||University of Iowa|
|Principal Investigator:||David Burks, MD||Henry Ford Hospital, Detroit|
|Principal Investigator:||Curtis Nickel, MD||Queen's University, Ontario, Canada|
|Study Chair:||Harris Foster, MD||Yale University|